Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor
Therapeutic Advances in Respiratory Disease · 2025-01 · 19
DOI: 10.1177/17534666251323194 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 31.03.2025. Verfasst von Vito Terlizzi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Medicine, Cystic Fibrosis Regional Reference Center, Meyer Children's Hospital IRCCS, Viale Gaetano Pieraccini 24, Florence, …. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Over the past decade, major clinical advances have been made in the healthcare and therapeutic development for cystic fibrosis (CF), a lethal genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR) protein. CFTR modulators represent innovative treatments that directly target the primary defects in the mutated CFTR protein and have demonstrated significant clinical benefits for many people with CF (pwCF) who are eligible for these treatments. In particular, the triple combination therapy composed of elexacaftor, tezacaftor, and ivacaftor (ETI) has changed the CF therapeutic landscape by significantly improving lung function, quality of life, and predicted survival rates. Here, we provided a comprehensive summary of the impact of ETI on clinical outcomes and the need for further research on long-term efficacy, side effects, pregnancy, possible drug–drug interactions, and extra-pulmonary manifestations. Moreover, a significant number of pwCF are unresponsive to these drugs or cannot afford their high costs. We, therefore, discussed health inequity issues and alternative therapeutic strategies under development aiming to obtain effective therapies for all pwCF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Medicine, Cystic Fibrosis Regional Reference Center, Meyer Children's Hospital IRCCS, Viale Gaetano Pieraccini 24, Florence, Italy.
- Department of Pediatrics, Cystic Fibrosis and Airway Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA.
ORCID-Profile: Vito Terlizzi
Zitieren
APA
Terlizzi, V., & Lopes-Pacheco, M. (2025). Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor. Therapeutic Advances in Respiratory Disease, 19. https://doi.org/10.1177/17534666251323194
Vancouver
Terlizzi V, Lopes-Pacheco M. Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor. Therapeutic Advances in Respiratory Disease. 2025;19. doi:10.1177/17534666251323194
BibTeX
@article{Terlizzi2025,
author = {Terlizzi, Vito and Lopes-Pacheco, Miquéias},
title = {Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2025},
volume = {19},
doi = {10.1177/17534666251323194}
}
EUVIMED